Clinical trials

AbCellera Granted U.S. Patent Covering its Trianni Mouse® Technology

Tuesday, January 19, 2021 - 9:41pm

AbCellera (Nasdaq: ABCL), a technology company with a centralized operating system for next-generation antibody discovery, today announced it has expanded its intellectual property (IP) portfolio to include its Trianni Mouse technology.

Key Points: 
  • AbCellera (Nasdaq: ABCL), a technology company with a centralized operating system for next-generation antibody discovery, today announced it has expanded its intellectual property (IP) portfolio to include its Trianni Mouse technology.
  • 10,881,084 titled Transgenic Animals and Methods of Use to Trianni, Inc. (Trianni), an AbCellera Company.
  • This patent is an important addition to our IP portfolio, providing protection to our proprietary technology in the U.S., said Carl Hansen, Ph.D., CEO of AbCellera and Trianni.
  • Triannis lead technology, the Trianni Mouse, is a next-generation platform enabling efficient generation of diverse, fully human monoclonal antibodies.

Syros Announces Proposed Offering of Common Stock

Tuesday, January 19, 2021 - 9:01pm

Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, announced today that it is offering to sell shares of its common stock in an underwritten public offering.

Key Points: 
  • Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, announced today that it is offering to sell shares of its common stock in an underwritten public offering.
  • Syros also intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock sold in the offering on the same terms and conditions.
  • This press release contains forward-looking statements, including, without limitation, statements regarding the anticipated use of proceeds from the proposed offering if the offering is consummated.
  • There can be no assurance that Syros will be able to complete the proposed offering on the anticipated terms, or at all.

Nilesh Patel Joins Cellanyx Board of Directors

Tuesday, January 19, 2021 - 7:45pm

Cellanyx today announced that Nilesh Patel has been appointed to the Cellanyx board of directors.

Key Points: 
  • Cellanyx today announced that Nilesh Patel has been appointed to the Cellanyx board of directors.
  • Nilesh is a private equity executive with an extensive background in strategy, operations, analytics and corporate finance.
  • Nilesh is an early investor in Cellanyx and shares its vision of developing novel cancer tests based on live tumor cell analysis and advanced AI technologies to enhance clinical decision making, said Pravin Chaturvedi, PhD, Cellanyx Executive Chairman.
  • Prior to CFC, Nilesh was vice president of strategy & portfolio development at Devonshire Investors the private equity arm of Fidelity Investments.

VeraSci Partners with ActiGraph to Expand the Use of Wearables in Clinical Trials

Tuesday, January 19, 2021 - 3:38pm

Preliminary data have indicated a correlation between remotely captured gait and actigraphy measures and established cognition and function measures.

Key Points: 
  • Preliminary data have indicated a correlation between remotely captured gait and actigraphy measures and established cognition and function measures.
  • These data suggest that wearables can provide meaningful information regarding cognitive health and may ultimately contribute to continuous assessment of cognition and function in clinical trials.
  • "Wearables present an incredible opportunity to gather data in ways that haven't been feasible before.
  • VeraSci is a clinical research company offering eClinical software, translation services, and expertise in endpoints and assessments.

Rapid, Cost-Efficient Sample Processing in Workflows such as COVID-19 Testing Enabled through Hamilton Storage and Rhinostics Partnership

Tuesday, January 19, 2021 - 3:00pm

The agreement includes joining Hamilton Storages LabElite DeCapper with the RHINOstic swab collection device for hands-free and high throughput sample processing.

Key Points: 
  • The agreement includes joining Hamilton Storages LabElite DeCapper with the RHINOstic swab collection device for hands-free and high throughput sample processing.
  • Were enthusiastic about working with Rhinostics as they apply a fresh perspective to an often-overlooked element of clinical laboratory workflows, said Matthew Hamilton, President of Hamilton Storage.
  • Hamilton Storage is a global leader in the design and manufacture of automated storage systems for biological and compound samples.
  • All trademarks are owned and/or registered by Hamilton Storage or Rhinostics in the U.S. and/or other countries.

 ImmunityBio Announces Phase I Trial of COVID-19 Vaccine Candidate in South Africa as New Variants of SARS-CoV-2 Spread

Tuesday, January 19, 2021 - 1:00pm

The same vaccine is currently being tested in a similar Phase I trial in the U.S., with no safety concerns identified to date.

Key Points: 
  • The same vaccine is currently being tested in a similar Phase I trial in the U.S., with no safety concerns identified to date.
  • These exciting results have catalyzed our interest in pursuing human trials of the oral vaccine in South Africa.
  • Understanding sensitivities related to adeno vaccine platforms in South Africa, we have taken the utmost care in designing our trial, said Dr. Amy Ward, principal investigator of the Phase I trial.
  • ImmunityBio has engaged with government agencies and indicated a commitment to ensuring this vaccine is available in South Africa.

NIH and PhysIQ Complete Initial Phase of COVID-19 Digital Biomarker Development; Pen Contract for Phase II

Tuesday, January 19, 2021 - 1:07pm

This exercise of Phase II by the NIH brings the total contract to $6.6 million.

Key Points: 
  • This exercise of Phase II by the NIH brings the total contract to $6.6 million.
  • View the full release here: https://www.businesswire.com/news/home/20210119005274/en/
    NIH enters Phase II of a multi-phase contract to continue physIQs development of an AI-based COVID-19 digital biomarker.
  • (Graphic: Business Wire)
    In just 10 weeks, physIQ successfully enrolled and monitored 400 high-risk COVID-19 patients in Phase I of the DeCODe study .
  • Phase II begins January 2021 where 1,200 patients will be enrolled to validate the digital biomarker.

Aptinyx Announces Publication of Review Article Highlighting Preclinical Data in Medicine in Drug Discovery Demonstrating the Potential of NYX-2925 to Treat Chronic, Centralized Pain Conditions

Tuesday, January 19, 2021 - 1:31pm

The data span across numerous preclinical models and highlight the potential therapeutic benefits of NYX-2925 in treating chronic, centralized pain conditions.

Key Points: 
  • The data span across numerous preclinical models and highlight the potential therapeutic benefits of NYX-2925 in treating chronic, centralized pain conditions.
  • This article in Medicine in Drug Discovery showcases our methodical approach to CNS drug development and also highlights the important role NYX-2925 could play in treating centralized chronic pain, said Norbert Riedel, Ph.D., chief executive officer of Aptinyx.
  • NYX-2925 is a novel oral NMDA receptor modulator currently in Phase 2 clinical development for the treatment of chronic pain.
  • In clinical studies, NYX-2925 has demonstrated activity that affects central pain processing, resulting in alleviation of pain and other symptoms associated with chronic pain conditions.

Compass Therapeutics to Participate in the B. Riley Securities Virtual Oncology Investor Conference

Tuesday, January 19, 2021 - 1:05pm

Compass Therapeutics, Inc. , a clinical-stage biotechnology company developing proprietary antibody therapeutics intended to engage the immune system to treat both solid tumors and hematological malignancies, today announced that Thomas Schuetz, MD, PhD, Co-Founder and Chief Executive Officer of Compass Therapeutics, will participate in a fireside chat at the B. Riley Securities Virtual Oncology Investor Conference.

Key Points: 
  • Compass Therapeutics, Inc. , a clinical-stage biotechnology company developing proprietary antibody therapeutics intended to engage the immune system to treat both solid tumors and hematological malignancies, today announced that Thomas Schuetz, MD, PhD, Co-Founder and Chief Executive Officer of Compass Therapeutics, will participate in a fireside chat at the B. Riley Securities Virtual Oncology Investor Conference.
  • The Compass presentation will be live webcast at 10:30 a.m. EST on January 21, 2021.
  • The presentation will be open to registered conference attendees, institutional investors and investor relations professionals, who may register to view the live webcast at https://b-riley-oncology-investor-conference.events.issuerdirect.com/signup .
  • Compass Therapeutics is a clinical-stage biopharmaceutical company developing proprietary antibody therapeutics intended to engage the immune system to treat both solid tumors and hematologic malignancies.

SwanBio Therapeutics Appoints Alison Lawton to Board of Directors

Tuesday, January 19, 2021 - 1:30pm

SwanBio Therapeutics (SwanBio), a gene therapy company advancing AAV-based therapies for the treatment of devastating, genetically defined neurological conditions, today announced the appointment of Alison Lawton to the companys Board of Directors.

Key Points: 
  • SwanBio Therapeutics (SwanBio), a gene therapy company advancing AAV-based therapies for the treatment of devastating, genetically defined neurological conditions, today announced the appointment of Alison Lawton to the companys Board of Directors.
  • We are honored to add Alison to our Board of Directors, to support our goal of bringing life-changing treatments to people living with devastating neurological conditions.
  • I am delighted to join the team at SwanBio at this inflection point in their development as they progress their gene therapy product candidates for patients with neurological diseases, said Ms. Lawton.
  • SwanBio Therapeutics is a gene therapy company that aims to bring life-changing treatments to people with devastating, genetically defined neurological conditions.